Phase 3 TRIDENT study
Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields
A phase 3, global, randomized study, will evaluate TTFields therapy concomitant with RT/TMZ in patients ≥18 years of age (≥22 years in the US) with ...
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT ...
The TRIDENT clinical trial is a randomized, open-label study designed to enroll 950 adult patients with newly diagnosed GBM. Following maximal ...
TRIDENT - Glioblastoma Clinical Trial - Novocure Trials
The TRIDENT trial (also known as the “EF-32 trial”) is a randomized, controlled study, testing the safety and efficacy of Tumor Treating Fields (TTFields) from ...
CTNI-09. TRIDENT PHASE 3 TRIAL (EF-32): FIRST-LINE TUMOR ...
TRIDENT (EF-32; NCT04471844) is an international, pivotal, phase 3 randomized trial comparing triple-combination of TTFields/radiotherapy/ ...
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor ...
TRIDENT is an international phase III randomized trial comparing standard RT with TMZ vs the triple combination of RT plus TMZ with concomitant TTFields.
Abstract CT061: TRIDENT phase 3 study (EF-32): First-line Tumor ...
Here we present a phase 3 study examining the efficacy and safety of TTFields therapy concomitant with RT/TMZ in patients with ndGBM.
Trident phase 3 trial (EF-32): first-line Tumor Treating Fields (TTFields
Glioblastoma: Clinical Research. Brain Tumor Research and Treatment. F-1106. Trident phase 3 trial (EF-32): first-line Tumor Treating Fields. (TTFields; 200 kHz) ...
A Study of Repotrectinib Versus Crizotinib in Participants With ...
... (TRIDENT-3) - CA127-1030. Updated: 22 October, 2024 | ClinicalTrials.gov. About This ... Trial Details. Phase 3. Phase. Gender(s). 18+. Age Range. 58. Location(s).
TRIDENT phase 3 study (EF-32): first-line Tumor Treating Fields ...
... Trials. TRIDENT phase 3 study (EF-32): first-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance ...
CTNI-74. PHASE 3 TRIDENT TRIAL: CONCOMITANT RADIATION ...
TRIDENT is an international phase III randomized trial comparing standard RT with TMZ vs the triple combination of RT/TMZ with concomitant ...
First Patient Enrolled in Novocure's Global Phase 3 TRIDENT Trial ...
Trident will enroll 950 newly diagnosed GBM patients who, after surgery or biopsy, are candidates for radiation therapy and temozolomide. The ...
QOL-15. THE PIVOTAL TRIDENT STUDY OF TUMOR TREATING ...
THE PIVOTAL TRIDENT STUDY OF TUMOR TREATING FIELDS (TTFIELDS) ... Phase III randomized study of radiation and temozolomide versus ...
Final Participant Registered in TRIDENT Phase 3 Glioblastoma Trial
The primary endpoint of the trial is overall survival, with secondary endpoints including progression-free survival, one-year and two-year ...
Repotrectinib Recruiting Phase 3 Trials for Non-Small Cell Lung ...
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small ...
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating ...
Businesswire 2024 - Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma open_in_new. "Novocure...announced that ...
Abstract CT061: TRIDENT phase 3 study (EF-32): First-line Tumor ...
Materials and Methods: TRIDENT (EF-32; NCT04471844) is a global, randomized, phase 3 study of patients ≥18 years of age (≥22 years in the US) ...
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT ...
The TRIDENT clinical trial is a randomized, open-label study designed to enroll 950 adult patients with newly diagnosed GBM. Following maximal ...
ASCO® 2023 Insights: "Phase 3 TRIDENT Study (EF-32) | VuMedi
A video from Wenyin Shi (as part of Insights from 2023 ASCO® Annual Meeting), posted on Jun 8, 2023.
Recent advances in Tumor Treating Fields (TTFields) therapy for ...
A randomized, controlled pivotal (phase III) study (TRIDENT; EF-32; NCT04471844) comparing the efficacy and safety of TTFields therapy ...